Women's need for information before attending genetic counselling for familial breast or ovarian cancer: a questionnaire, interview, and observational study

Citation for published version:

Digital Object Identifier (DOI):
10.1136/bmj.314.7076.281

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
BMJ

Publisher Rights Statement:
© 1997 BMJ Publishing Group Ltd

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Information in practice

Information needed to decide about cardiovascular treatment in primary care

John Robson

Abstract

There is growing consensus that treatment of cardiovascular risks should be based on multiple rather than single factors and on absolute rather than relative risks. Thresholds for treatment should reflect the level of absolute risk at which the benefits and hazards of treating outweigh the benefits and hazards of not treating. Once a decision has been made to initiate a treatment programme, clinicians need to know the patient's absolute risk. At this level of risk, do the benefits of treatment outweigh the hazards? Given this information, which treatment option does the patient prefer? Using cardiovascular disease as an example, I review some measures that assist decision making in primary care. Practice guidelines should routinely include accessible presentation of treatment outcomes on benefit, hazard, and costs for a range of absolute risks. These measures enable patients and their doctors to weigh the pros and cons of treatment in their particular circumstances.

Introduction

There are three main sources of information guiding decisions about cardiovascular treatment. Cohort studies provide information on multiple risk factors and subsequent cardiovascular events, so that a person's absolute risk may be estimated from a score. Risk might be considered high if the chance of death or disease from a major coronary event exceeded 6% a year (60% in 10 years). However, risk alone reveals nothing about the advisability of drug treatment, and, although cardiovascular risk scores have been available for more than 20 years, uncertainty about their role has hindered integration into routine clinical practice. The second source, based on clinical trials, yields at a particular level of risk a variety of treatment outcomes, including the "number needed to treat," years of life gained, adverse events, and costs. The third source of information is the person to be treated, who, given an informed choice of treatment outcomes, can indicate his or her preference.

Assessing cardiovascular risk

Cardiovascular risk scores were originally designed to facilitate behavioural change by communicating the degree of risk to clinicians and patients. More recently, they have been used to target treatment more effectively, because prediction of risk is improved when based on multiple rather than single risk factors. Relative risk scores such as the Dundee score, may have a continuing role in behavioural change, particularly among lower risk groups at younger ages. However, relative risk has been criticised as a method of allocating treatment, and absolute risk (from which relative risk may be derived) is preferable.

The main coronary risk scores are based on data from the American Framingham study, the British regional heart study, and Scottish survey and British trial data (Dundee score). All were specifically devised to influence primary care doctors. The Framingham study has the advantages of longer follow up over a wider age range for both sexes and is expressed as absolute risk. In addition, it has shown that the ratio of serum total cholesterol concentration to high density lipoprotein cholesterol is a considerably better predictor than total cholesterol concentration alone. Five or 10 year risks may be estimated and scores tabulated by age so that the effects of multiple risk factors can be compared over time. It has the disadvantage that it is based on an American population. Scores are also available for the risk of stroke.

Recent cardiovascular guidelines in Europe and New Zealand adapted the Framingham data and incorporated other risk factors such as obesity and family history. This has made the risk equations more user friendly and has taken some account of specialists in hypertension, who variably recommend treatment at diastolic thresholds of 90, 95, and 100 mm Hg even though data from both Framingham and the Medical Research Council indicate that systolic pressure is a considerably better predictor of stroke.

Because prediction depends on the prevalence of the condition, none of the risk scores has a high predictive value. The scores overestimate risk, and only 60% of those subjects at highest risk (in the top 10% of the risk distribution) will actually have a coronary event within the next 10 years. Prediction is considerably worse at younger ages and lower levels of risk. Factors not included in the score, such as family history of cardiovascular disease (first degree relative aged under 55) or obesity, may mean that risks are higher than predicted. Social class and ethnic group may also be relevant. Nevertheless, for all their limitations, multiple risk scores are the best available tools for predicting risk and are superior to any one factor alone.
The adoption of absolute, rather than relative, risk as the criterion for treatment inevitably prioritises older age groups. On this basis, healthy men aged under 50 years with a serum cholesterol concentration of ≤9 mmol/l do not require drug treatment. Although their relative risk is high compared with their peers with a serum cholesterol concentration of 5 mmol/l, even if they smoke and have raised blood pressure they are unlikely to reach a coronary event rate of 3% a year, the threshold at which the Sheffield group considers treatment appropriate. Advice to stop smoking, exercise, and improve their diet remains the mainstay of intervention.

### Treatment thresholds and treatment outcomes

Once a person's absolute risk has been estimated how is the threshold at which treatment is indicated to be decided? More information is needed, and patients and their doctors require summaries of the hazards, benefits, and costs of treatment.

Risk scores describe the level, distribution, and relative importance of different factors but give no information on the outcomes resulting from treatment. The final choice of treatment is affected by the choice of outcome, cause of death or disease, deaths prevented or number needed to treat, years of life lost or gained, adverse events or indicators of quality of life, and cost. Should treatment of raised blood pressure depend on the risk of stroke or the risk of heart attack or both? Other outcomes may be decisive factors in treatment. The impact of diabetes on risk of stroke is modest, but the impact of raised blood pressure on diabetic renal disease is considerable.

### Benefits of treatment

The manner in which benefits are expressed is particularly important. Expressing values as numbers needed to treat gives equal weight to the risk of dying from a heart attack at the age of 75 as at age 40. However, if years of life gained rather than numbers of deaths were used as the outcome, intervention would include more younger people and fewer older people. Both measures are useful, as each expresses a different component of outcome. An important gain in mean life expectancy would be about 60 days. This is not so small a gain as it seems, as it is averaged over all people receiving treatment. For example, if all cancer were eradicated the mean gain in life expectancy would be 60 years. It is not so small a gain as it seems, as it is averaged over all people receiving treatment. If, for example, if all cancer were eradicated the mean gain in life expectancy would be only one year, although for the people who would otherwise have developed cancer the gain would be measured in decades.

The format in which these outcomes are presented may influence choice of treatment. Thus, presenting results in terms of years of life gained may lead to different treatments being preferred than when results are given as numbers needed to treat, and relative risk may result in lower treatment thresholds than absolute risk.

The number needed to treat to prevent one event or death is the reciprocal of the absolute difference in outcome between the treatment and control groups in a clinical trial and is a measure of the absolute efficacy of treatment. Assuming a 30% reduction in coronary heart disease as a result of treatment with "statins" (hydroxymethylglutaryl coenzyme A reductase inhibitors), 1332 people at low risk (with an annual coronary event rate of 0.05%) would require treatment for five years to prevent one coronary event. In contrast, 20 people would need treatment for five years to prevent one event if their annual risk was 3%. Table 1 shows the number needed to treat for different levels of risk.

### Adverse effects and quality of life

There is most uncertainty about treating the many people at intermediate risk, rather than the smaller group at high risk who have most to gain from treatment. Small changes in the threshold of treatment in the intermediate range can turn large numbers of people into lifelong patients. Clinicians should require a high level of confidence in the extent of the benefits and hazards to convince them that treatment of such patients is worth while because small but serious risks applied to large numbers can transform gains in one area into a net loss. If recommendations are uncertain or contradictory, patients and doctors require more information, accessibly presented, about the hazards and benefits of treatment so that they can make their own judgments.

Quality of life may be valued more than years of life, and the adverse effects of treatment may be decisive in the choice of treatment. In the Medical Research Council trial of treatment of mild hypertension, for each cardiovascular event prevented, 33 men experienced adverse reactions (impotence and fatigue being prominent) and 20% stopped treatment as a result. Although adverse effects of treatment can be incorporated in the concept of years of quality adjusted life gained, the subjective perception of hazards can have profound effects on the choice of both patients and public. This is shown by the unpopularity of prostatic surgery for urinary symptoms: after the risks and benefits of different treatments had been explained, the degree of inconvenience caused by the treatment and concern about impotence were the most important predictors of choice, and only 20% of men with severe symptoms opted for surgery. Given an informed choice, patients often express preferences that are different from those of their doctors or peers.

Decision analysis is able to concurrently assess the impact of multiple components, including quality of life, on treatment options, but many questions remain. What is a reasonable number needed to treat or cost per year of life gained? How sensitive is the analysis to alterations in parameters? Do the results need further qualification for population subgroups?
Cost and workload
The monetary cost of different treatments may be compared through cost-effectiveness analysis. Because gains are often fairly small, the conclusions of such analyses can be highly sensitive to minor changes in parameters, including drug costs.13 While this may not be a problem when comparing two treatments under similar conditions or the incremental gains of extending a programme, it is a major issue when working out the basic costs of a programme for treating mild hypertension.14 In addition, equity is omitted as a consideration in most analyses,15 although there is no reason in principle why it should not be incorporated.16 Policy decisions may be influenced by both workload and the overall cost of a programme. These are determined by the size of the target population, and any new programme identifying treatment for more than 2% of the population has major implications for workload in primary care.2 At a policy level, consideration should be given to whether greater benefit may be obtained at the same cost from some other intervention.

Accessible summaries of treatment outcomes
These aids to decision making offer no tablets of stone. Instead, they provide estimates of the limits of uncertainty and a means to compare the relative value of different options. The presentation of a range of outcomes may not solve the problem, but it does establish a common currency in which options are explicit and decisions may be shared.17 I discuss the use of such measures in the current debates on the treatment of raised blood pressure and cholesterol.

Managing hypertension
While the New Zealand and European cardiovascular guidelines usefully summarise cardiovascular risk, neither provide an accessible summary of the numbers needed to treat, years of life gained, adverse event rates, costs, or workload at each level of absolute risk. Doubts remain about treating mild hypertension at younger ages. For example, 400 men aged 52 with systolic blood pressure <150 mm Hg would require treatment for five years to prevent one stroke. This number falls to 250 for systolic pressure of 150-169 mm Hg and to 100 for systolic pressure of 170-199 mm Hg.18 19 Lifetime treatment is estimated to add an average of 30 to 64 days to life expectancy; at 1995 prices, the cost ranged from £14 000 to £82 000 for men (greatest in the youngest age groups) and from £28 000 to £252 000 for women (greatest in the youngest age groups). For example, 400 men aged 52 with systolic blood pressure <150 mm Hg would require treatment for five years to prevent one stroke. This number falls to 250 for systolic pressure of 150-169 mm Hg and to 100 for systolic pressure of 170-199 mm Hg.18 19 Lifetime treatment is estimated to add an average of 30 to 64 days to life expectancy; at 1995 prices, the cost ranged from £14 000 to £82 000 for men (greatest in the youngest age groups) and from £28 000 to £252 000 for women (greatest in the youngest age groups).

Patients and doctors need easy access to such data to inform their decisions. Table 2 shows a summary of outcome measures that might be included in future guidelines. It is not until annual cardiovascular risk is 1.5% or more that the benefits of treating raised blood pressure begin to become clear.20 While a national strategy to reduce dietary salt and obesity would have considerably more impact than drug treatment, and at considerably less cost,21 patients and their doctors must, for now, rely on evidence of this kind to inform their choice of treatment.

Managing serum cholesterol
The management of serum cholesterol presents greater uncertainty, although this is now changing for high risk patients. For people with heart disease and serum cholesterol above 6.5 mmol/l, and possibly at lower levels, treatment with “statins” to reduce cholesterol confers benefit.22 23 For people without heart disease at lower absolute risk, recommendations for drug treatment based solely on their relative risk due to raised cholesterol have been controversial. The European Atherosclerosis Group24 and a Sheffield group25 26 have attempted to resolve the dilemma by recommending that treatment be based on absolute risk calculated with data from the Framingham study. Even with these more conservative guidelines, the number of people for whom treatment is recommended is substantially higher than reviews of previous trials seem to warrant. For people without pre-existing heart disease, adverse effects of treatment may be decisive, and further large scale trials are necessary to establish lower limits for treatment.27 28 The west of Scotland study indicates that, among healthy men with an average serum cholesterol concentration of 7 mmol/l and annual coronary event risk of 1.5%, 200 people would require treatment for five years to prevent one coronary death and 40 would require treatment for this period to prevent one coronary event.29 Table 3 compares the results of this study with those of the Scandinavian simvastatin survival study.30 Again, this simple summary of Table 3 Summary of outcomes of treatment with “statins” to reduce serum cholesterol concentration in people with and without pre-existing heart disease (Source of data: Scandinavian Simvastatin Survival Study Group,30 Shepherd et al,31 Yusuf et al32)

<table>
<thead>
<tr>
<th>Pre-existing heart disease</th>
<th>Yes*</th>
<th>No†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean serum cholesterol concentration (mmol/l)</td>
<td>6.7</td>
<td>7.0</td>
</tr>
<tr>
<td>Annual risk of coronary event (%)</td>
<td>6</td>
<td>1.5</td>
</tr>
<tr>
<td>Number needed to treat for five years:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>To prevent one coronary death</td>
<td>28</td>
<td>200</td>
</tr>
<tr>
<td>To prevent one coronary event</td>
<td>15</td>
<td>40</td>
</tr>
<tr>
<td>No of patients experiencing adverse effects per coronary death prevented</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Cost per year of life gained (£)§</td>
<td>17 000</td>
<td>Not available</td>
</tr>
<tr>
<td>Proportion of population proposed for treatment (%)</td>
<td>0.3</td>
<td>20</td>
</tr>
</tbody>
</table>

*Scandinavian study of men and women with mean age 58 years.
†West of Scotland study of men with mean age 55 years.
‡There was also a non-significant 12% excess of non-coronary deaths among women.
§At prices in 1995.
treatment outcomes would enhance future guidelines, although gains in life years were not available at the time, nor were costs in the Scandinavian study. Even at the low levels of adverse reaction reported, for every one person gaining from prevention of coronary death, two or three people would experience adverse effects from treatment. It is in these areas of uncertainty that there is the greatest need for accessible presentation of available data.

Conclusion

Absolute multiple risk scores usefully summarise risk and are better predictors than any single factor. However, risk is only half the story. Accessible presentation of numbers needed to treat, years of life gained, adverse events, cost, and workload is also needed for shared decision making, enabling patients and their clinicians to weigh the pros and cons of treatment in their particular circumstances. These measures should be routinely included in management guidelines. Decision tools may only approximate to the truth, but pre-sent a range of treatment outcomes establishes a common currency for informed choice. Placing finite limits on uncertainty is the best guarantee that treatment will be optimal and appropriate.1

I thank Carol Deazeux, Kambiz Boomla, Gene Feder, Rod Jackson, Anna Livingstone, Pat McBride, and the referees who commented on this article.

Funding: I wrote this article while on study leave funded by the Department of Health, the Royal College of General Practitioners, and the King's Fund.

Conflict of interest: None.

23 Richardson WS, Deticky AS, Users’ guides to the medical literature. VII. How to use a clinical decision analysis. B. What are the results and will they help me in caring for my patients? JAMA 1995;273:1613-8.
26 Gunayt GH, Sackett DL, Cook DJ. Users’ guide to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? JAMA 1994;271:159-63.

(Accepted 9 January 1997)
Women’s need for information before attending genetic counselling for familial breast or ovarian cancer: a questionnaire, interview, and observational study

N Hallowell, F Murton, H Statham, J M Green, M P M Richards

Abstract

Objectives: To describe women’s information needs prior to genetic counselling for familial breast or ovarian cancer.

Design: Prospective study including semistructured telephone interviews before genetic counselling; observations of consultations, completion of postal questionnaires, and face-to-face interviews within two months of counselling.

Subjects: 46 women attending genetic counselling for familial breast or ovarian cancer.

Main outcome measures: Subjects’ understanding of process and content of genetic counselling before attending and attitudes about their preparation for the counselling session.

Results: Although all women interviewed before the clinic expected to discuss their risk of developing cancer and risk management options, there was evidence of a lack of knowledge about the process and content of genetic counselling; 17 (37%) women said they did not know what else would happen. Most women interviewed after counselling viewed it positively, but 26 (55%) felt they had been inadequately prepared and 11 (28%) felt that their lack of preparation meant that they could not be given an accurate estimation of their risk of cancer.

Conclusions: Some women felt that they did not obtain optimum benefit from genetic counselling because they were inadequately prepared for it. We suggest that cancer family history clinics should provide women with written information about the process and content of genetic counselling before their clinic attendance.

Introduction

As the genetic basis for common multifactorial disorders becomes increasingly recognised there will be increasing demand for genetic counselling. It is therefore important to determine efficient ways of providing this service. Recent studies have looked at the provision of information during genetic consultations and counsellees’ expectations before attending cancer family history clinics. Using data obtained during a prospective study of genetic counselling for breast or ovarian cancer, we present suggestions for the use of written information by family history clinics.

Subjects and methods

We recruited subjects from Cambridge Cancer Family History Clinic. After excluding those who had had breast or ovarian cancer or who had previously attended genetic counselling, we invited all women referred between February 1994 and February 1995 to take part. We approached 59 eligible women and recruited 46. The participants were aged 22-59 years (mean 40 years), and table 1 shows details of their family history of cancer.

Data collection

We collected data from interviews, observations, and questionnaires (see table 2). We recorded and transcribed the interviews and consultations with the women’s consent. The study was approved by Cambridge Local Research Ethics Committee.

Data analysis

We coded the interview transcripts using the computer package Atlas-ti (Thomas Muhr, Berlin). Categories were based on the interview questions and recurring themes identified. The consultations were coded as agenda setting, family history, epidemiological, genetic, risk and screening information, surgery, hormone therapy, DNA testing, and other. We analysed the questionnaire data with the statistical package spss.

Clinic procedures

Before their appointment, counsellors were sent a form asking them to list affected relatives and their

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Timing and method of data collection from 46 women attending genetic counselling for familial cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timing</td>
<td>Method</td>
</tr>
<tr>
<td>1 Week before consultation</td>
<td>Semistructured telephone interview</td>
</tr>
<tr>
<td>Consultation</td>
<td>Observation</td>
</tr>
<tr>
<td>2-4 Weeks after consultation</td>
<td>Postal questionnaire</td>
</tr>
<tr>
<td>4-8 Weeks after consultation</td>
<td>Semistructured face to face interview</td>
</tr>
</tbody>
</table>
Table 3 Response of 42 women who attended genetic counselling for familial breast or ovarian cancer to the question “Overall, how satisfied are you with your experience of genetic counselling?”

<table>
<thead>
<tr>
<th>Degree of satisfaction</th>
<th>No (%) of women</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 (very satisfied)</td>
<td>23 (55)</td>
</tr>
<tr>
<td>4</td>
<td>12 (26)</td>
</tr>
<tr>
<td>3</td>
<td>5 (12)</td>
</tr>
<tr>
<td>2</td>
<td>4 (9)</td>
</tr>
<tr>
<td>1</td>
<td>6 (14)</td>
</tr>
</tbody>
</table>

Responses to postclinic interview

Although 16 (40%) women said that they had not known what to expect, most participants regarded counselling as a positive experience. However, only 14 (35%) women reported feeling adequately prepared—

“...if there was anything I could change, it would be to let somebody know earlier what it really entails. Because I didn’t know what to expect; I didn’t know...they’re going to talk to you about your family history. They are going to relate your family history to histories that they already have.”

Eleven (28%) women said that they would have liked to have known beforehand exactly what details of family history were needed. Some had not realised the importance of male or distant relatives or that they would be asked for health details of family members not affected with cancer. They worried that the gaps in their information meant that they were unable to obtain an accurate estimate of risk, despite the fact that the counsellors always stressed the provisional nature of estimating risk.

Two (5%) women wished that they had been advised to prepare questions, as they had not realised that counselling was a two way process. Four (10%) women who received a qualitative risk estimate said it would have been helpful if they had been given a numerical risk, and two were not aware that this was possible.

Six (15%) women said the consultation did not match up to their expectations: four had thought that they would have a blood test (it was unclear whether they envisaged this as diagnostic or DNA testing), and two had expected to have a clinical examination or screening—“I had no idea what was going to happen. I thought maybe I was going to have a full examination... I’ve never had a mammogram, and I thought maybe that would happen.”

Some women said their anxiety about what would occur or the information they might receive had affected the way they approached the consultation—“I was in such a state when I got there. [My friend] and I sat in the car counting down... And I’m saying to [my
Suggested content of information leaflet about genetic counselling

Description of process of genetic counselling as practised in clinic—This should inform counsellees about what will occur during their consultation; that their family health history will be discussed, whether blood may be taken, and whether screening or physical examination may be performed. It should also emphasise that counselling is a two way exchange and encourage counsellees to prepare questions for the counsellor. An indication of whether it would be appropriate for a partner or close relative to attend the consultation would be helpful.

Description of content of genetic discussions—This should outline the topics that may be discussed during the consultation: family history, risk assessment, and options for risk management for both counsellee and relatives. A list of all the details of the family history that the counsellor needs to bring to the consultation should be included. It should be emphasised that information about all known blood relatives, male and female and not just those affected by cancer, may be helpful.

Background information—This should include brief epidemiological facts about the cancers (for example, the population risk of breast cancer is 1 in 12 and about 5% of cases of breast cancer are caused by an inherited predisposition), a simplified illustration of autosomal dominant inheritance, and a brief description of current research into cancer genes and the implications for DNA testing.

Discussion

Our subjects reported a high degree of satisfaction with counselling, but uncertainty about what the consultation entailed meant that a substantial proportion did not formulate questions in advance. Indeed, only 35% of the women considered themselves adequately prepared. Most knew that they wanted information about their risk of cancer and 38 (83%) received a quantitative risk estimate, but 11 (28%) felt that their lack of preparation meant that they could not obtain a definitive risk estimate. These findings suggest that counsellees would benefit from receiving information about the process and content of genetic consultations before they attend. A cost effective way to implement this suggestion would be to send counsellees a leaflet describing the practice of genetic counselling in a particular clinic and including some background information about familial breast and ovarian cancer (see box).

Many studies report that patients often prefer written to oral information1 and that receiving written information before treatment reduces anxiety,2 is reassuring,3 and increases patient satisfaction.4 5 We believe that the service delivery in cancer family history clinics could be improved by the use of written information, as it would not only allay anxiety about the forthcoming consultation but also focus counsellees’ concerns and ensure they bring the relevant information. This may reduce the need for clinics to contact counsellees for further information and the number of requests for follow up consultations.

We thank Professor B A J Ponder, Dr C Eng, Maggie Ponder, and all the women who took part in this study.

Funding: This study was funded by the Medical Research Council. The familial cancer clinic was supported by grants from the Cancer Research Campaign to B A J Ponder.

Conflict of interest: None.


(Accepted 8 January 1997)
Netlines

Medline on the web

- One of the best biomedical sites on the web has just got better. The United States National Center for Biotechnology Information at the National Library of Medicine has for some time offered free access to a subset of Medline dealing with genetics as part of its Entrez series of interlinked databases (http://www4.ncbi.nlm.nih.gov/Entrez/). Now the whole of Medline is available on the site through an experimental service, PubMed (http://www4.ncbi.nlm.nih.gov/PubMed/). In PubMed retrieved citations are not only linked to related articles or sequences, as in the Entrez databases, but there is also a PreMedLine section, containing references to articles that have not yet made it into the official Medline database.

- You can even include hypertext links in your own web documents to articles in PubMed (such as http://www4.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8520280&form=6&db=m&Dopt=m) or, more powerfully still, call up a whole swath of related articles in a single web address (try http://www4.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&uid=8520280&Dopt=m).

Kawasaki disease

- Following complaints on television that too many British doctors are ignorant of Kawasaki disease, the Royal College of General Practitioners has prepared a fact sheet (http://www.rcgp.org.uk/news/rcn0009.htm), which is available on the RCGP’s excellent web site (http://www.rcgp.org.uk/index.html).

- Those keen to know more about the aetiology of the condition should consult an article by Nigel Curtis of St Mary’s Medical School available on line on http://www.sm.ic.ac.uk/paediatrics/kawa_cml.htm

- Support for families affected by the disease is available from the Kawasaki Families’ Network (http://ourworld.compuserve.com/homespages/kawasaki/). The network can also be contacted by email on kawasaki@compuserve.com

Government information on the web

- If you tend to misfile or throw away the paper versions of official government communications, don’t despair—you can access government press releases on the Central Office of Information’s web site (http://www.coi.gov.uk/coi/). Of particular relevance here are the Department of Health’s press releases (http://www.coi.gov.uk/coi/depts/DH/DH.html).

- The Department of Health itself has its own home page (http://www.open.gov.uk/dothome.html), nested within the government information service (http://www.open.gov.uk/). On the DoH home page you will find a search facility plus links to DoH publications. Several mouse clicks down the line you will find the full text of (so far) only one government white paper on health (http://www.the-stationery-office.co.uk/publicat/bydoth.htm), published by the newly privatised successor to HMSO, the Stationery Office (http://www.the-stationery-office.co.uk)

Talking digital

- In his book Being Digital (see http://tulpi.interconnect.com.au/~pg/Negrop.htm for a review) Nicholas Negroponte envisages a world where everyday devices are networked and have enough intelligence to talk to one another, so that the refrigerator can talk, say, to your car or to your toaster.

- Perhaps one day your electrocardiograph will be able to talk directly to the Cardiac Arrhythmia Advisory System (CAAS) at the University of Oklahoma Health Sciences Center (http://wailer.uokhsu.edu/einthoven.html). This expert system is able to interpret and advise on electrocardiograms over the web.

- According to its creators, its intended uses include decision support for rural and non-specialist practitioners and continuing medical education. Although still in demonstration mode, CAAS will accept interesting electrocardiograms for analysis in digital or in deadtree format.

- In a similar vein to CAAS is Hepaxpert (http://www.ping.at/hepax/), a program that will interpret serology results for hepatitis A and B over the web.

- On a more technical level, communication between medical imaging devices will be made easier by the launch of a new standard for digital imaging and communications in medicine, termed DICOM 3 (http://www.xray.hmc.psu.edu/dicom/dicom_home.html). The new standard provides a detailed specification for formatting and exchanging images between imaging devices. For a tutorial on DICOM, particularly as DICOM 3 relates to cardiology, see http://www.xray.hmc.psu.edu/dicom/acc_tut/tutorial.html

E coli O157:H7 and meningococcal meningitis

- The closing months of 1996 were marked in Britain by outbreaks of E coli O157:H7 infection and meningococcal meningitis. The Public Health Laboratory Service has published online fact sheets about E coli O157:H7 on http://www.open.gov.uk/cdsc/ecolifac.htm and about meningococcal disease on http://www.open.gov.uk/cdsc/mengfact.htm

- Further information on E coli as a pathogen is available from the E coli index at the University of Birmingham (http://sun1.bham.ac.uk/bcm4ght6/res.html) and from the American Food and Drug Administration’s Bad Bug Book (http://vm.cfsan.fda.gov/~mow/intro.html).

- Those keen to keep up to date with emerging infections worldwide should visit the home page of the Program for Monitoring Emerging Diseases (ProMED) on http://www.healthnet.org/programs/promed.html and or join the ProMED mailing list by sending an email with the message “subscribe promed [your email address]” to majordomo@usa.healthnet.org, leaving the subject line blank

Compiled by Mark Pallen

email m.pallen@ic.ac.uk

web page http://www.qmw.ac.uk/~rhbm001/mpallen.html

If you are not yet on line you can find help in getting connected in the ABC of Medical Computing (eds Nicholas Lee and Andrew Millman, BMJ Publishing), which has Mark Pallen’s Guide to the Internet as a supplement.